Marc Reitman, MD
Child & Adolescent Psychiatry · Huntington, NYNPI 1245395151
Payments from drug & device makers
Across 674 payments — averaging $19.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- AbbVie$2K
- Teva Pharmaceuticals USA, Inc.$1K
- Otsuka America Pharmaceutical, Inc.$1K
- Lundbeck LLC$952
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$775
- plus $5K from 27 others
What the payments were for
- Food & beverage$12,960100%
- Education$470%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 120 | $2,019 |
| AbbVie(2 entities) | 78 | $1,568 |
| Teva Pharmaceuticals USA, Inc. | 62 | $1,319 |
| Otsuka America Pharmaceutical, Inc. | 62 | $1,162 |
| Lundbeck LLC | 49 | $952 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 45 | $775 |
| Alkermes, Inc. | 30 | $679 |
| Neurocrine Biosciences, Inc. | 28 | $629 |
| Johnson & Johnson | 21 | $490 |
| Sunovion Pharmaceuticals Inc. | 20 | $372 |
| Supernus Pharmaceuticals, Inc. | 15 | $351 |
| Corium, LLC | 20 | $331 |
| Bausch Health US, LLC | 16 | $317 |
| Neos Therapeutics, LP | 20 | $317 |
| Tris Pharma Inc | 16 | $279 |
| Ironshore Pharmaceuticals Inc. | 14 | $246 |
| Merck | 10 | $185 |
| Axsome Therapeutics, Inc. | 9 | $183 |
| Almatica Pharma LLC | 6 | $124 |
| Vanda Pharmaceuticals Inc. | 6 | $108 |
| Neuronetics, Inc. | 3 | $86 |
| Shire North American Group Inc | 3 | $73 |
| Idorsia Pharmaceuticals US Inc | 3 | $67 |
| Alfasigma USA, Inc. | 3 | $63 |
| Collegium Pharmaceutical, Inc. | 2 | $49 |
| Adlon Therapeutics L.p. | 2 | $48 |
| Noven Therapeutics, LLC | 2 | $44 |
| Arbor Pharmaceuticals, Inc. | 2 | $40 |
| Eisai Inc. | 2 | $38 |
| E.r. Squibb & Sons, L.L.C. | 2 | $34 |
| Novo Nordisk | 1 | $22 |
| Avanir Pharmaceuticals, Inc. | 1 | $22 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$480
How this compares
$13,007 in reported general payments places this provider in the 95th percentile of 317 child & adolescent psychiatry providers in New York.
See all child & adolescent psychiatry providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrintellixVortioxetine Hydrobromide | 63 | $74,086 |
| VraylarCariprazine Hcl | 14 | $30,111 |
| RexultiBrexpiprazole | 19 | $26,429 |
| VyvanseLisdexamfetamine Dimesylate | 32 | $24,662 |
| QuviviqDaridorexant Hcl | 36 | $19,619 |
| AuvelityDextromethorphan Hbr/Bupropion | 14 | $14,211 |
| Clomipramine Hcl | 44 | $6,435 |
| Bupropion XlBupropion Hcl | 205 | $6,425 |
| Duloxetine Hcl | 176 | $6,195 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 136 | $4,923 |
| KlonopinClonazepam | 14 | $4,327 |
| Lisdexamfetamine Dimesylate | 11 | $3,201 |
| Aripiprazole | 51 | $3,200 |
| Atomoxetine Hcl | 11 | $2,296 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 33 | $2,210 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $2,019 | $98,74795 claims |
| AbbVieVraylar | $1,568 | $30,11114 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,162 | $26,42919 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $67 | $19,61936 claims |
| Axsome Therapeutics, Inc.Auvelity | $183 | $14,21114 claims |
| Almatica Pharma LLCSertraline Hcl | $124 | $1,15792 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 317 child & adolescent psychiatry providers in New York.
Other child & adolescent psychiatry in Huntington
- Alexander KolevzonNew York$490K
- Jeffrey NewcornNew York$465K
- Matthew LorberNew York$398K
- Mitchell CabisudoNew Windsor$346K
- Aleksandra DjukicBronx$332K
- Jeremy Veenstra-VanderweeleNew York$224K
- Parinda ParikhWhite Plains$185K
- John MarinoCanandaigua$70K
- Beth SmithBuffalo$65K
- Iliyan IvanovNew York$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.